A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 IN PATIENTS WITH ADVANCED SOLID TUMORS
A Study of BA3021 in Patients with Advanced Solid Tumors (Lung Cancer, Triple Negative Breast Cancer, or Soft Tissue Sarcoma)
Sponsor: BioAtla LLC
Enrolling: Male and Female Patients
IRB Number: AAAS0590
U.S. Govt. ID: NCT03504488
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: BioAtla (the sponsor of the clinical trial) is studying BA3021 as a potential treatment for varieties of cancers including but not limited to lung, triple negative breast cancer and soft tissue sarcoma. The purpose of this research study is to test the safety of different doses of BA3021 and to find out what effects, good and/or bad, it has on the body and the cancer.
This study is closed
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have lung, triple negative breast cancer or soft tissue sarcoma? Yes No
Does your cancer continue to grow despite therapy? Or, are you not eligible for therapy or refuse standard of care therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162